{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:04:22Z","timestamp":1792260262157,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00210-023-02716-x","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T10:02:32Z","timestamp":1695204152000},"page":"1421-1431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"397","author":[{"given":"Kuo Chao","family":"Yew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Rui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phei Ching","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Yang","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-3794","authenticated-orcid":false,"given":"Chong Yew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"2716_CR1","unstructured":"American Association for the Study of Liver Diseases (2022). Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org. Accessed 27 Feb 2023."},{"key":"2716_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12916-017-0815-7","volume":"15","author":"TF Baumert","year":"2017","unstructured":"Baumert TF, Juhling F, Ono A, Hoshida Y (2017) Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 15:52. https:\/\/doi.org\/10.1186\/s12916-017-0815-7","journal-title":"BMC Med"},{"key":"2716_CR3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/jvh.13507","volume":"28","author":"AA Butt","year":"2021","unstructured":"Butt AA, Yan P (2021) Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: results from ERCHIVES. J Viral Hepat 28:916\u2013924. https:\/\/doi.org\/10.1111\/jvh.13507","journal-title":"J Viral Hepat"},{"key":"2716_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","volume":"71","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Celsa C, Calvaruso V et al (2019) Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 71:265\u2013273. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.027","journal-title":"J Hepatol"},{"issue":"10179","key":"2716_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C et al (2019) Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 393(10179):1453\u20131464. https:\/\/doi.org\/10.1016\/s0140-6736(18)32111-1","journal-title":"Lancet"},{"key":"2716_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MCM Cheung","year":"2016","unstructured":"Cheung MCM, Walker AJ, Hudson BE et al (2016) Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65:741\u2013747. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.019","journal-title":"J Hepatol"},{"key":"2716_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A et al (2016) Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 65:727\u2013733. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.015","journal-title":"J Hepatol."},{"key":"2716_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19090","volume":"19","author":"C Crossan","year":"2015","unstructured":"Crossan C, Tsochatzis EA, Longworth L et al (2015) Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 19:1\u2013409. https:\/\/doi.org\/10.3310\/hta19090","journal-title":"Health Technol Assess."},{"key":"2716_CR9","doi-asserted-by":"publisher","first-page":"e004172","DOI":"10.1136\/bmjopen-2013-004172","volume":"4","author":"S Denford","year":"2014","unstructured":"Denford S, Frost J, Dieppe P, Cooper C, Britten N (2014) Individualisation of drug treatments for patients with long-term conditions: a review of concepts. BMJ Open 4:e004172. https:\/\/doi.org\/10.1136\/bmjopen-2013-004172","journal-title":"BMJ Open"},{"key":"2716_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25058","volume":"21","author":"S Fourati","year":"2018","unstructured":"Fourati S, Feld JJ, Chevaliez S, Luhmann N (2018) Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 21:e25058. https:\/\/doi.org\/10.1002\/jia2.25058","journal-title":"J Int AIDS Soc"},{"key":"2716_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","volume":"3","author":"CT Frenette","year":"2019","unstructured":"Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG (2019) A practical guideline for hepatocellular carcinoma screening in patients at risk. Mayo Clin Proc Innov Qual Outcomes 3:302\u2013310. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2019.04.005","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2716_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","volume":"68","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara N, Friedman SL, Goossens N, Hoshida Y (2018) Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 68:526\u2013549. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.016","journal-title":"J Hepatol"},{"key":"2716_CR13","unstructured":"Gastroenterological Society of Australia (2022) Australian recommendations for the management of hepatitis C virus infection: a consensus statement. https:\/\/www.hepcguidelines.org.au\/"},{"key":"2716_CR14","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3748\/wjg.14.4300","volume":"14","author":"AI Gomaa","year":"2008","unstructured":"Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14:4300\u20134308. https:\/\/doi.org\/10.3748\/wjg.14.4300","journal-title":"World J Gastroenterol"},{"key":"2716_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12072-019-09933-8","volume":"13","author":"AS Hanafy","year":"2019","unstructured":"Hanafy AS, Bassiony MA, Basha MAA (2019) Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated? Hepatol Int. 13:165\u2013172. https:\/\/doi.org\/10.1007\/s12072-019-09933-8","journal-title":"Hepatol Int."},{"key":"2716_CR16","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide. 1st ed","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa T, Ebert D (2021) Doing meta-analysis with R: a hands-on guide. 1st ed. Chapman and Hall\/CRC"},{"key":"2716_CR17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/meg.0000000000001195","volume":"30","author":"LA Hill","year":"2018","unstructured":"Hill LA, Delmonte RJ, Andrews B et al (2018) Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol 30:1378\u20131383. https:\/\/doi.org\/10.1097\/meg.0000000000001195","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2716_CR18","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1038\/srep09954","volume":"5","author":"CS Hsu","year":"2015","unstructured":"Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH (2015) Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma. Sci Rep 5:9954. https:\/\/doi.org\/10.1038\/srep09954","journal-title":"Sci Rep"},{"key":"2716_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/hep.29855","volume":"68","author":"AC Huang","year":"2018","unstructured":"Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA (2018) Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 68:449\u2013461. https:\/\/doi.org\/10.1002\/hep.29855","journal-title":"Hepatology"},{"key":"2716_CR20","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s10620-017-4739-z","volume":"62","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Kawamura Y, Kobayashi M et al (2017) Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 62:2932\u20132942. https:\/\/doi.org\/10.1007\/s10620-017-4739-z","journal-title":"Dig Dis Sci"},{"key":"2716_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","volume":"129","author":"Y Imai","year":"1998","unstructured":"Imai Y, Kawata S, Tamura S et al (1998) Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 129:94\u201399. https:\/\/doi.org\/10.7326\/0003-4819-129-2-199807150-00005","journal-title":"Ann Intern Med"},{"key":"2716_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1053\/gast.2002.31474","volume":"122","author":"MM Lai","year":"2002","unstructured":"Lai MM (2002) Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 122:568\u2013571. https:\/\/doi.org\/10.1053\/gast.2002.31474","journal-title":"Gastroenterology"},{"key":"2716_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12972","volume":"286","author":"JV Lazarus","year":"2019","unstructured":"Lazarus JV, Pericas JM, Picchio C et al (2019) We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 286:503\u2013525. https:\/\/doi.org\/10.1111\/joim.12972","journal-title":"J Intern Med"},{"key":"2716_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/13651820410024021","volume":"7","author":"TY Leong","year":"2005","unstructured":"Leong TY, Leong AS (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7(1):5\u201315. https:\/\/doi.org\/10.1080\/13651820410024021","journal-title":"HPB (Oxford)"},{"key":"2716_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/pds.2148","volume":"20","author":"V Lo Re","year":"2011","unstructured":"Lo Re V, Lim JK, Goetz MB et al (2011) Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 20:689\u2013699. https:\/\/doi.org\/10.1002\/pds.2148","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2716_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-019-0476-8","volume":"121","author":"J Louro","year":"2019","unstructured":"Louro J, Posso M, Hilton Boon M et al (2019) A systematic review and quality assessment of individualised breast cancer risk prediction models. Br J Cancer 121:76\u201385. https:\/\/doi.org\/10.1038\/s41416-019-0476-8","journal-title":"Br J Cancer"},{"key":"2716_CR27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/jvh.13186","volume":"26","author":"C Lusivika-Nzinga","year":"2019","unstructured":"Lusivika-Nzinga C, Fontaine H, Dorival C, Simony M, Pol S, Carrat F (2019) The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. J Viral Hepat 26:1489\u20131492. https:\/\/doi.org\/10.1111\/jvh.13186","journal-title":"J Viral Hepat"},{"key":"2716_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB (2021) Epidemiology of hepatocellular carcinoma. Hepatology 73:4\u201313. https:\/\/doi.org\/10.1002\/hep.31288","journal-title":"Hepatology"},{"issue":"4","key":"2716_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/apt.14427","volume":"47","author":"F Mettke","year":"2018","unstructured":"Mettke F, Schlevogt B, Deterding K et al (2018) Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 47(4):516\u2013525. https:\/\/doi.org\/10.1111\/apt.14427","journal-title":"Aliment Pharmacol Ther."},{"key":"2716_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1. https:\/\/doi.org\/10.1186\/2046-4053-4-1","journal-title":"Syst Rev"},{"key":"2716_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/hep.31732","volume":"74","author":"H Park","year":"2021","unstructured":"Park H, Jiang X, Song HJ et al (2021) The impact of direct-acting antiviral therapy on end-stage liver disease among individuals with chronic hepatitis C and substance use disorders. Hepatology 74:566\u2013581. https:\/\/doi.org\/10.1002\/hep.31732","journal-title":"Hepatology"},{"key":"2716_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/hep.30303","volume":"69","author":"H Park","year":"2019","unstructured":"Park H, Wang W, Henry L, Nelson DR (2019) Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States. Hepatology 69:1032\u20131045. https:\/\/doi.org\/10.1002\/hep.30303","journal-title":"Hepatology"},{"key":"2716_CR33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/2050640619841254","volume":"7","author":"CM Preda","year":"2019","unstructured":"Preda CM, Baicus C, Sandra I et al (2019) Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir\/paritaprevir\/ritonavir+dasabuvir+ribavirin therapy. United European Gastroenterol J 7:699\u2013708. https:\/\/doi.org\/10.1177\/2050640619841254","journal-title":"United European Gastroenterol J"},{"key":"2716_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/liv.13659","volume":"38","author":"B Roche","year":"2018","unstructured":"Roche B, Coilly A, Duclos-Vallee JC, Samuel D (2018) The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 38:139\u2013145. https:\/\/doi.org\/10.1111\/liv.13659","journal-title":"Liver Int."},{"issue":"1683-1692","key":"2716_CR35","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N et al (2019) Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a Multicenter North American Cohort Study. Gastroenterology 156(1683-1692):e1681. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.027","journal-title":"Gastroenterology"},{"key":"2716_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/apt.14593","volume":"47","author":"AW Singer","year":"2018","unstructured":"Singer AW, Reddy KR, Telep LE et al (2018) Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 47:1278\u20131287. https:\/\/doi.org\/10.1111\/apt.14593","journal-title":"Aliment Pharmacol Ther"},{"key":"2716_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","volume":"15","author":"J Smith-Palmer","year":"2015","unstructured":"Smith-Palmer J, Cerri K, Valentine W (2015) Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis 15:19. https:\/\/doi.org\/10.1186\/s12879-015-0748-8","journal-title":"BMC Infect Dis"},{"key":"2716_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"1","key":"2716_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001049","volume":"7","author":"CS Tse","year":"2021","unstructured":"Tse CS, Yang JD, Mousa OY et al (2021) Direct-acting antiviral therapy in liver transplant patients with hepatocellular carcinoma and hepatitis C. Transplant Direct 7(1):e635. https:\/\/doi.org\/10.1097\/txd.0000000000001049","journal-title":"Transplant Direct"},{"key":"2716_CR40","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/liv.13456","volume":"37","author":"V Virlogeux","year":"2017","unstructured":"Virlogeux V, Pradat P, Hartig-Lavie K et al (2017) Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int 37:1122\u20131127. https:\/\/doi.org\/10.1111\/liv.13456","journal-title":"Liver Int"},{"key":"2716_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5114\/ceh.2017.71483","volume":"3","author":"K Warzyszy\u0144ska","year":"2017","unstructured":"Warzyszy\u0144ska K, Jonas M, Wasiak D, Kosieradzki M, Ma\u0142kowski P (2017) Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment - preliminary report. Clin Exp Hepatol 3:194\u2013197. https:\/\/doi.org\/10.5114\/ceh.2017.71483","journal-title":"Clin Exp Hepatol"},{"key":"2716_CR42","unstructured":"World Health Organisation (WHO) (2022) Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 11 June 2022"},{"key":"2716_CR43","unstructured":"World Health Organisation (WHO) (2018) Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531733. Accessed 31 August 2023."},{"key":"2716_CR44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/lt.24790","volume":"23","author":"A Zanetto","year":"2017","unstructured":"Zanetto A, Shalaby S, Vitale A et al (2017) Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl 23:1103\u20131112. https:\/\/doi.org\/10.1002\/lt.24790","journal-title":"Liver Transpl"},{"key":"2716_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007","volume":"18","author":"MJ Zoratti","year":"2020","unstructured":"Zoratti MJ, Siddiqua A, Morassut RE et al (2020) Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine 18:100237. https:\/\/doi.org\/10.1016\/j.eclinm.2019.12.007","journal-title":"EClinicalMedicine"},{"key":"2716_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5009\/gnl15257","volume":"10","author":"RX Zhu","year":"2016","unstructured":"Zhu RX, Seto WK, Lai CL, Yuen MF (2016) Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 10:332\u2013339. https:\/\/doi.org\/10.5009\/gnl15257","journal-title":"Gut Liver"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02716-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:17:06Z","timestamp":1707549426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02716-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2716"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02716-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}